Breaking News

Financial Report: Novo Nordisk

Modern insulins boost YTD growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novo Nordisk 1H11

1H Revenues: $6.1 billion (+9%)

1H Earnings: $1.6 billion (+19%)

Comments: Insulin sales were up 10% to $2.6 billion, driven by NovoRapid ($1.2 billion +7%), Levemir ($701.9 million +11%) and Victoza ($452.9 million +253%). Biopharmaceutical sales were $1.5 billion, up 5%. NovoSeven were up 5% to $804.7 million.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters